WO2020091041A1 - Procédé de préparation de milieu de culture liquide - Google Patents

Procédé de préparation de milieu de culture liquide Download PDF

Info

Publication number
WO2020091041A1
WO2020091041A1 PCT/JP2019/043031 JP2019043031W WO2020091041A1 WO 2020091041 A1 WO2020091041 A1 WO 2020091041A1 JP 2019043031 W JP2019043031 W JP 2019043031W WO 2020091041 A1 WO2020091041 A1 WO 2020091041A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid medium
polypeptide
medium
cells
antibody
Prior art date
Application number
PCT/JP2019/043031
Other languages
English (en)
Japanese (ja)
Inventor
就介 平
須澤　敏行
Original Assignee
協和キリン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 協和キリン株式会社 filed Critical 協和キリン株式会社
Priority to US17/290,365 priority Critical patent/US20210403971A1/en
Priority to EP19878782.2A priority patent/EP3875595A4/fr
Priority to JP2020554981A priority patent/JP7453151B2/ja
Publication of WO2020091041A1 publication Critical patent/WO2020091041A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids

Definitions

  • the present invention provides a method for preparing a liquid medium, a liquid medium prepared by the method, a method for culturing cells using the liquid medium prepared by the method, and a polypeptide having a desired quality using the method.
  • the present invention relates to a method and a polypeptide having a desired quality produced using the production method.
  • the high manufacturing cost of biopharmaceuticals compared to small molecule drugs is a challenge in the pharmaceutical industry.
  • the liquid medium used for cell culture needs to contain sufficient amounts of a plurality of nutrients necessary for cell growth and production of physiologically active substances which are active ingredients of biopharmaceuticals.
  • a liquid medium used for cell culture contains, as components, amino acids, nucleic acids, saccharides, lipids, vitamins, metals, inorganic salts and derivatives thereof, and these components are liquid. It is used by cells in a state of being dissolved in a medium, and is used for cell growth, survival, and production of physiologically active substances.
  • Non-Patent Document 1 the concentration of copper contained in a liquid medium used for cell culture affects cell growth or productivity, or the quality of antibodies produced.
  • Non-Patent Document 3 it has been recommended to use a filtration step using a 0.1 ⁇ m membrane for the purpose of removing mycoplasma as well as removal of microorganisms, and development of a filtration membrane capable of removing potential viruses has also been promoted.
  • Liquid medium is prepared by dissolving powdered medium in a solvent, but if some of the medium components are not dissolved in the solvent in the dissolution process, the insoluble components will be removed in the filtration process. Therefore, in the process of preparing the liquid medium, the medium components must be effectively dissolved in the solvent before the filtration step so that the composition of the medium does not change before and after the filtration step.
  • the present inventors have found that particularly when a liquid medium is prepared on a large scale, the solubility of the medium component in a solvent is lowered, and the medium component changes before and after filtration. Moreover, it was found for the first time that when a polypeptide is produced using a liquid medium prepared on a large scale, the amount of variants, which are impurities derived from the polypeptide, increases.
  • the present invention provides a method for preparing a liquid medium in which a medium component is effectively dissolved in a solvent, a liquid medium prepared by the method, a method for culturing cells using the liquid medium prepared by the method, and the culture.
  • the present invention relates to a method for producing a polypeptide having a desired quality using a method and a polypeptide having a desired quality produced by using the method.
  • the present inventors diligently investigated a method for preparing a medium containing a desired amount of components. As a result, in the process of preparing the liquid medium, it was found that by controlling the oxygen concentration during medium preparation, the medium components can be effectively dissolved in the solvent, and a liquid medium containing the desired components and amounts can be prepared. The invention was completed.
  • a method for preparing a liquid medium comprising the step of dissolving a powdered medium in a solvent in the presence of oxygen.
  • 2. The method for preparing a liquid medium according to 1 above, wherein the powder medium contains copper or a derivative thereof.
  • the copper or its derivative is a simple substance of copper, an oxide, a salt or a hydrate thereof.
  • 4. The copper or its derivative is copper (II) sulfate pentahydrate, copper (II) chloride dihydrate, copper (I) chloride or copper (II) nitrate trihydrate or a mixture thereof.
  • the method for preparing a liquid medium according to item 3. 5. 5 The copper (II) sulfate pentahydrate, copper (II) chloride dihydrate, copper (I) chloride or copper (II) nitrate trihydrate or a mixture thereof.
  • the method for preparing a liquid medium according to any one of 1 to 4 above which comprises a step of adding cysteine, cystine or a derivative thereof. 6.
  • the method for preparing a liquid medium according to any one of 1 to 5 above which comprises at least one operation selected from the following (i) and (ii): (I) An operation in which a gas containing oxygen is ventilated on the upper surface to bring the gas into contact with the solvent, and (ii) an operation in which the gas containing oxygen is sparged into the solvent. 7.
  • the method for preparing a liquid medium according to any one of 1 to 6 above which comprises an operation of stirring the solvent. 8. 8.
  • the method for preparing a liquid medium according to any one of 1 to 7 above which further comprises a membrane filtration step after the step of dissolving the powdered medium in the solvent in the presence of oxygen.
  • 9. The method for preparing a liquid medium according to the above 8, wherein the copper concentration in the liquid medium does not substantially change before and after the membrane filtration.
  • 10. The method for preparing a liquid medium according to 8 or 9, wherein the filtration membrane used for the membrane filtration has a pore size of 1 nm to 100 ⁇ m.
  • the method for preparing a liquid medium according to any one of 1 to 10 above which comprises a step of measuring a dissolved oxygen concentration in the solvent or the liquid medium. 12. 12.
  • the method for preparing a liquid medium according to any one of 1 to 11 above which comprises a step of measuring a dissolved oxygen concentration in the solvent or the liquid medium before or during the preparation of the liquid medium. 13.
  • the solvent is 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% of the saturated dissolved oxygen amount. Or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more or 100% of oxygen, 1 to 12 above
  • 16. A method for culturing cells using the liquid medium described in 15 above. 17.
  • 17. The method for culturing a cell according to the above 16, wherein the cell expresses a polypeptide. 18.
  • 18. The method for culturing cells as described in 17 above, wherein the polypeptide is an antibody.
  • the method for culturing cells according to any one of 16 to 18 above, wherein the cells are animal cells. 20. 20. The method for culturing cells according to the above 19, wherein the animal cell is a Chinese hamster ovary cell. 21. 21.
  • a cell expressing a desired polypeptide is cultivated in the liquid medium described in 15 above, the polypeptide is produced and accumulated in the culture, and the polypeptide is collected from the culture.
  • 27. A polypeptide produced using the production method described in any one of 22 to 26 above.
  • 28. 16 A method of controlling the production of a variant derived from the polypeptide, which comprises using the liquid medium according to 15 above, in the step of culturing cells expressing the polypeptide. 29. 29.
  • 29. 29. A method of controlling the production of the variant of 28, wherein said polypeptide is an antibody.
  • 31. The method for controlling the production of the variant according to any one of 28 to 30, wherein the cell is an animal cell. 32.
  • the present inventors have included a step of dissolving a powdered medium in a solvent in the presence of oxygen in a method for preparing a liquid culture medium for cell culture, thereby controlling the oxygen concentration during the preparation of the medium to achieve an effective effect. It was found for the first time that a liquid medium containing desired components and amounts can be prepared by dissolving the medium components in a solvent. Furthermore, the present inventors have found that the obtained liquid medium containing the desired components and amounts can be used for cell culture to produce a polypeptide having a desired quality.
  • a method for preparing a liquid medium in which a medium component is effectively dissolved in a solvent, a liquid medium prepared by the method, a method for culturing cells using the liquid medium prepared by the method, the culture A method for producing a polypeptide having a desired quality using the method and a polypeptide having a desired quality produced using the method can be provided.
  • FIG. 1A shows the copper concentration of a medium prepared by adding a powdered medium to water and then stirring the mixture for a predetermined time while aerating air.
  • the black bar graph shows the copper concentration of the medium before filtration
  • the white bar graph shows the copper concentration of the medium after filtration.
  • FIG. 1B shows the copper concentration of the medium prepared by adding the powder medium to water and then stirring the mixture for a predetermined time while aerating nitrogen.
  • the black bar graph shows the copper concentration of the medium before filtration
  • the white bar graph shows the copper concentration of the medium after filtration.
  • FIG. 2 shows the copper concentration of the liquid medium prepared under each dissolved oxygen concentration condition.
  • the black bar graph shows the copper concentration of the medium before filtration
  • the white bar graph shows the copper concentration of the medium after filtration.
  • FIG. 3 shows the ratio of Basic Peaks of the antibody obtained by culturing antibody-producing cells using a liquid medium prepared under each dissolved oxygen concentration condition.
  • the present invention relates to a method for preparing a liquid medium, which comprises a step of dissolving a powdered medium in a solvent in the presence of oxygen.
  • the medium in the present invention can be appropriately selected from commercially available media, and two or more types of media may be mixed. Further, known media described in the literature can also be selected. A desired trophic factor can be appropriately selected and added to these media. Further, the medium may be composed of components in which desired nutritional factors are appropriately selected.
  • the medium in the present invention may be any of synthetic medium, semi-synthetic medium and natural medium. Examples thereof include basal medium, serum-containing medium, serum-free medium, medium containing no animal-derived component, protein-free medium or completely synthetic medium, and preferably serum-free medium, protein-free medium or completely synthetic medium.
  • basal medium of the present invention examples include RPMI1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], Dulbecco modified MEM (DMEM). Medium [Virology, 8, 396 (1959)], 199 medium [Proceeding of the Society for for the the Biological Medicine, 73, 1 (1950)], F12 medium (LTI) [Proc. Natl. Acad. Sci.
  • Iscove's modified Dulbecco's medium [J.Experimental Medicine, 147, 923 (1978)]
  • EX-CELL (registered trademark) 302 medium EX-CELL (registered trademark) 325 medium ( SAFC Bioscience Co., Ltd.)
  • CHO-S-SFMII medium Invitrogen
  • commercial medium such as these, modified medium and mixed medium, and the like, and preferably R MI1640 medium, DMEM medium, F12 medium, IMDM, EX-CELL (R) 302 medium or hybridoma SFM medium (manufactured by Invitrogen) and the like.
  • the serum-containing medium in the present invention for example, basal medium, bovine, mammalian serum such as horse, bird animal serum such as chicken, fish animal serum such as yellowtail, or a fraction of the above serum, 1 Examples include those to which more than one kind of serum or serum fraction has been added.
  • the serum-free medium in the present invention include a basal medium to which nutrient factors, physiologically active substances and the like, which are alternatives to serum, are added.
  • the substance added in place of the animal-derived component a physiologically active substance produced by a gene recombination method, a hydrolyzate or a lipid containing no animal-derived raw material, etc. Can be mentioned.
  • Examples of the protein-free medium in the present invention include ADPF medium (Animal derived protein free medium, manufactured by Hyclone), CD-Hybridoma medium (manufactured by Invitrogen), CD-CHO medium (manufactured by Invitrogen), IS-CD- Examples thereof include CHO medium (manufactured by Irvine Scientific), EX-CELL (registered trademark) CD-CHO medium (manufactured by SAFC Bioscience), and the like.
  • ADPF medium Animal derived protein free medium, manufactured by Hyclone
  • CD-Hybridoma medium manufactured by Invitrogen
  • CD-CHO medium manufactured by Invitrogen
  • IS-CD- Examples thereof include CHO medium (manufactured by Irvine Scientific), EX-CELL (registered trademark) CD-CHO medium (manufactured by SAFC Bioscience), and the like.
  • Examples of the medium in the present invention include a medium for culturing microorganisms, a medium for culturing insect cells, a medium for culturing yeast cells, a medium for culturing plant cells, a medium for culturing animal cells, and the like, preferably animals.
  • a medium for cell culture is used.
  • any medium suitable for cell culture can be used, but preferably, medium for animal cell culture is mentioned, more preferably Chinese hamster ovary (CHO) cells.
  • a culture medium may be used.
  • the medium in the present invention is not particularly limited, and examples thereof include expansion culture medium, basal (starting) medium, feed (fed-batch) medium and reflux medium.
  • any medium existing in powder form can be used.
  • the powder medium in the present invention also includes a medium existing in a granular form.
  • the production method of the powder medium in the present invention is not particularly limited, but preferably, the production method by a mixing process such as disk mill, ball mill, pin mill, etc. of dry ingredients, or the production by freeze-drying of a pre-made liquid medium. Methods and the like.
  • the method for producing a powdery medium existing in the form of granules in the present invention is not particularly limited, and examples thereof include Advanced Granulation Technology (registered trademark) and the like. Also, a step of spraying a solution in which at least one kind of material selected from the group consisting of natural paste, synthetic paste, sugar, and fats and oils is sprayed to the finely divided components and dried is also included. Good.
  • the liquid medium in the present invention is not particularly limited, but preferably includes a medium capable of culturing cells and the like.
  • the liquid medium in the present invention is prepared by dissolving a powder medium in a solvent.
  • any solvent can be used as long as the powder medium is dissolved, and examples thereof include water or an aqueous solution containing a nutrient factor and / or a buffer component in advance. Further, the liquid medium can be used as a solvent.
  • the amount of the solvent used to prepare the liquid medium is not particularly limited as long as it is an amount suitable for preparing the desired amount of the liquid medium necessary for the production of the desired polypeptide, but the desired culture scale Alternatively, it is prepared in the range of 10 L to 10000 L depending on the size of the culture vessel.
  • the nutritional factors in the present invention include carbon sources such as sugars and nitrogen sources such as amino acids, and particularly sugars, amino acids, vitamins, lipids, nucleic acids, physiologically active substances, fatty acids, organic acids, proteins, hydrolysates or metals or The salt etc. are mentioned. Further, these compounds may form a salt such as a hydrochloride, a sulfate, a nitrate, a sodium salt, a potassium salt or an ammonium salt and / or a solvate such as a hydrate.
  • the saccharide in the present invention may be any of monosaccharide, oligosaccharide and polysaccharide and is not particularly limited.
  • sugar derivatives such as deoxy sugar, uronic acid, amino sugar or sugar alcohol are also included.
  • glucose, mannose, galactose, fructose, ribose, arabinose, ribulose, erythrose, erythrulose, glyceraldehyde, dihydroxyacetone, sedoheptulose, maltose, lactose, sucrose and the like can be mentioned, and one or more kinds can be used in combination.
  • the amino acid in the present invention is not particularly limited, but for example, L-alanine (Ala), L-arginine (Arg), L-asparagine (Asn), L-aspartic acid (Asp), L-cysteine (Cys), L-glutamic acid (Glu), L-glutamine (Gln), glycine (Gly), L-histidine (His), L-isoleucine (Ile), L-leucine (Leu), L-lysine (Lys), L-methionine (Met), L-phenylalanine (Phe), L-proline (Pro), L-serine (Ser), L-threonine (Thr), L-tryptophan (Trp) or L-valine (Val), and the like, They may be used alone or in combination of two or more. Also, multimers such as cystine may be used. It may be added as a peptide or a multimer thereof, and examples thereof include L-alanyl-L
  • the vitamin in the present invention is not particularly limited, and examples thereof include d-biotin, D-pantothenic acid, choline, folic acid, myo-inositol, niacinamide, pyridoxal, riboflavin, thiamine, cyanocobalamin or DL- ⁇ -tocopherol. These are used alone or in combination of two or more.
  • the lipid in the present invention is not particularly limited, but examples thereof include cholesterol, linoleic acid, linoleic acid and the like.
  • physiologically active substance in the present invention is not particularly limited, but examples thereof include serum fraction containing insulin, transferrin, serum albumin or growth factor, and the like. These physiologically active substances also include physiologically active substances produced by gene recombination technology or chemical synthesis technology.
  • the hydrolyzate in the present invention is not particularly limited, and examples thereof include hydrolysates or extracts of soybean, wheat, rice, pea, cottonseed, fish or yeast extract and the like. Specific examples include SOY HYDROLYSATE UF (manufactured by SAFC Bioscience, catalog number: 91052-1K3986 or 91052-5K3986).
  • the metal in the present invention is not particularly limited, for example, lithium, sodium, potassium, magnesium, calcium, iron, manganese, zinc, molybdenum, vanadium, copper, cadmium, rubidium, cobalt, zirconium, germanium, nickel, tin, Chromium, silicon, etc. are mentioned, and they are used singly or in combination of two or more.
  • the buffer component in the present invention is not particularly limited, for example, sodium hydrogen carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium hydrogen carbonate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium acetate, Examples thereof include acetic acid, sodium citrate, citric acid and the like.
  • the components of the powder medium or liquid medium in the present invention preferably include copper, cysteine, cystine and / or their derivatives.
  • the copper or its derivative in the present invention is not particularly limited, but includes simple substance of copper, oxide, and salt or hydrate thereof.
  • the copper oxide include copper (I) oxide and copper (II) oxide.
  • the copper salt include copper (I) cyanide, copper (II) sulfate pentahydrate, copper (II) chloride dihydrate, copper (I) chloride or copper (II) nitrate trihydrate.
  • copper (II) sulfate pentahydrate, copper (II) chloride dihydrate, copper (I) chloride or copper (II) nitrate trihydrate are preferred.
  • the concentration in the prepared liquid medium is 1 ng / mL to 1 ⁇ g / mL, preferably 1 to 100 ng / mL, more preferably 5 ng / mL to 50 ng / mL.
  • cysteine or derivatives thereof in the present invention include, but are not limited to, L-cysteine, cysteine hydrochloride, cysteine hydrochloride monohydrate, acetylcysteine, glutathione and the like.
  • the cystine or derivative thereof in the present invention is not particularly limited, and examples thereof include L-cystine, cystine dihydrochloride, L-cystine disodium salt and the like.
  • Cysteine, cystine or their derivatives are added so that the concentration in the prepared liquid medium is, for example, 1 ⁇ g / mL to 10 mg / mL.
  • Cysteine, cystine or a derivative thereof may be added to a powder medium containing other components and then dissolved in a solvent, or cysteine, cystine or a derivative thereof may be dissolved in a solvent separately from the powder medium containing other components. You may add. When cysteine, cystine or a derivative thereof is added to the solvent separately from the powder medium containing the other components, cysteine, cystine or a derivative thereof may be added before the powder medium containing the other components, It may be added later.
  • oxygen is supplied by allowing a gas containing oxygen to be ventilated from the upper surface of the container for dissolving the powdered medium and bringing the gas into contact with the solvent or the liquid medium to be prepared.
  • oxygen-containing gas may be supplied by sparging in a solvent or a liquid medium to be prepared.
  • the gas containing oxygen is not particularly limited as long as it contains oxygen, and examples thereof include pure oxygen, a mixture of oxygen and another gas, or air.
  • the gas containing oxygen is a mixture of oxygen and another gas
  • the other gas may be nitrogen, argon, helium, carbon dioxide or the like.
  • these gases and oxygen are prepared and supplied at an arbitrary mixing ratio.
  • the concentration or amount of oxygen supplied is not particularly limited as long as the medium components such as copper are sufficiently dissolved and does not cause precipitation, but the solvent or the prepared 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92 of the saturated dissolved oxygen content %, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more or 100% of oxygen is preferably adjusted. More preferably, the saturated dissolved oxygen amount is maintained at 20% or more, further preferably 40% or more.
  • the solvent or the prepared liquid medium is allowed to stand or agitate in the presence of oxygen.
  • the holding or stirring is performed for a period during which the powder medium such as copper is completely dissolved and its concentration can be stably maintained. Specifically, it is carried out for 10 minutes to 10 days, preferably 30 minutes to 24 hours, more preferably 30 minutes to 6 hours.
  • the powdered medium and oxygen can also be dissolved by spontaneous mixing by aerating a gas containing oxygen from the lower surface of the solvent or the liquid medium to be prepared.
  • the amount of oxygen supplied during preparation of the liquid medium of the present invention is, for example, 1 to 500 mL / min, preferably 10 to 100 mL / min, relative to the solvent or the liquid medium prepared per liter.
  • the concentration or amount of oxygen supplied to the solvent or the liquid medium to be prepared is determined by measuring the dissolved oxygen concentration contained in the solvent or the liquid medium to be prepared by an optical or polarographic method before or during the preparation of the liquid medium. It can be easily controlled by measuring. By confirming that the oxygen concentration is appropriately adjusted while measuring the dissolved oxygen concentration, it is possible to determine the dissolution of the powder medium such as copper.
  • the powder medium may be added to the solvent at once, or may be added in plural times. Further, the powder may be put into a medium preparation container filled with a solvent to dissolve it, or the solvent may be added after the powder has been put into the medium preparation container first.
  • the use of the prepared liquid medium is not particularly limited, but it can be used for cell culture after further filtering using a filtration membrane. That is, the method for preparing a liquid medium of the present invention may further include a step of membrane filtration after the step of dissolving the powder medium in a solvent in the presence of oxygen.
  • the method of membrane filtration is not particularly limited as long as it is a method of permeating a liquid medium to be treated through a porous membrane by pressure and removing unwanted substances such as microorganisms, components, particles or contaminants in the solution, Preferred are a microfiltration method, an ultrafiltration method, a dialysis method, an electrodialysis method or a reverse osmosis method, more preferably a microfiltration method, an ultrafiltration method or a dialysis method. Particularly preferred is a microfiltration method.
  • the membrane in the present invention is not particularly limited, but preferably includes a microfiltration membrane, an ultrafiltration membrane, a dialysis membrane, an electrodialysis membrane or a reverse osmosis membrane. More preferably, a microfiltration membrane, an ultrafiltration membrane or a dialysis membrane is used. Particularly preferred is a microfiltration membrane.
  • the pore size of the filtration membrane used for membrane filtration is not particularly limited as long as the liquid medium can be sterilized, but is preferably 1 nm to 100 ⁇ m, more preferably 5 nm to 10 ⁇ m, and more preferably 10 nm to 1 ⁇ m. Is. Particularly preferably, it is 0.1 ⁇ m to 0.5 ⁇ m.
  • the material of the membrane used in the present invention is not particularly limited, but for example, cellulose acetate, aromatic polyamide, polyacrylonitrile, polyvinyl chloride, polyvinyl chloride-polyacrylonitrile copolymer, polysulfone, polyether sulfone (PES). , Polyvinylidene fluoride (PVDF), ceramics, polyvinyl alcohol, polyvinyldendifluoride, acetic acid-nitric acid mixed ester of cellulose, polytetrafluoroethylene, alumina, styrene-divinylbenzene copolymer, tetrafluoroethylene, etc. or their derivatives, etc. Is mentioned.
  • PVDF Polyvinylidene fluoride
  • ceramics polyvinyl alcohol, polyvinyldendifluoride, acetic acid-nitric acid mixed ester of cellulose, polytetrafluoroethylene, alumina, styrene-div
  • filtration membrane using polyether sulfone or its derivative examples include Millipore Express (registered trademark) PLUS Membrane Filters (pore size: 0.22 ⁇ m or 0.45 ⁇ m) (manufactured by Millipore), Millipore Express SHC cartridge filter ( Millipore), Millipore Express SHR cartridge filter (Millipore), Supor EBV (Pall), Supor EKV (Pall, catalog number: AB3EKV7PH4), Supor Life 200 (Pal), registered as Supor Life (Pal).
  • Millipore Express registered trademark PLUS Membrane Filters (pore size: 0.22 ⁇ m or 0.45 ⁇ m) (manufactured by Millipore), Millipore Express SHC cartridge filter ( Millipore), Millipore Express SHR cartridge filter (Millipore), Supor EBV (Pall), Supor EKV (Pall, catalog number: AB3EKV7PH4), Supor Life 200 (Pal), registered as Supor Life (P
  • filtration membrane using polyvinylidene fluoride or its derivative examples include Durapre (registered trademark) Membrane Filters (pore size: 0.10, 0.22, 0.45, 0.65, or 5.0 mm) ( Millipore), Durapore II Hydrophilic Filter Cartridge GV (manufactured by Millipore), Durapore II Hydrophilic Filter DFLP-LP-II (Millipore) registered trademark, Flora LP-In II-made by Millipore Corp. ), Fluorodyne II-DJLP (manufactured by Pall), Ultipore VF-DV20 (manufactured by Pall) or Ultipore VF-DV50. Pall Co., Ltd.), and the like.
  • Durapre registered trademark
  • Membrane Filters pore size: 0.10, 0.22, 0.45, 0.65, or 5.0 mm
  • Millipore Durapore II Hydrophilic Filter Cartridge GV (manufactured by Millipore), Dura
  • filtration membrane in which polyethersulfone or its derivative and polyvinylidene fluoride or its derivative are combined include Fluorodyne (registered trademark) EX Grade EDF Membrane Filter Cartridge (Pall, catalog number: AB3UEDF7PH4).
  • Omnipore registered trademark
  • Membrane Filters pore size: 0.1, 0.2, 0.45, 1.0, 5.0, Or 10 ⁇ m
  • MF-Millipore registered trademark
  • Membrane Filters pore size: 0.025, 0.05, 0.1, 0.22, 0.3, 0.45, 0.65, 0) .8, 1.2, 3, 5, or 8 ⁇ m
  • Nylon Membrane Filters pore size: 0.20 or 5.0 ⁇ m) (manufactured by Millipore), Ultipore N66 (pore size: 0.2, Or 0.45 ⁇ m) (manufactured by Pall)
  • Posidyne registered trademark
  • the filtration membrane used in the present invention may have a single filtration membrane structure such as Millex filter unit (manufactured by Millipore, catalog number: SLGV033RS). 5 / 0.2 ⁇ m Express SHC Disk W / Typer (Millipore, Catalog No .: HGEP02550) with one or more pre-filters attached to it so that it has two or more layers of membranes or two or more membranes. May be combined.
  • Millex filter unit manufactured by Millipore, catalog number: SLGV033RS
  • 5 / 0.2 ⁇ m Express SHC Disk W / Typer (Millipore, Catalog No .: HGEP02550) with one or more pre-filters attached to it so that it has two or more layers of membranes or two or more membranes. May be combined.
  • the liquid medium prepared in the present invention is characterized in that the component concentration in the liquid medium does not substantially change before and after membrane filtration. That the component concentration in the liquid medium does not substantially change before and after the membrane filtration means that, for example, when the component is copper, the liquid after the membrane filtration with respect to the copper concentration in the liquid medium before the membrane filtration. It means that the ratio of the copper concentration in the medium is preferably 0.7 to 1.3, more preferably 0.8 to 1.2, and most preferably 0.9 to 1.1.
  • the present invention also relates to a method for culturing cells using the liquid medium prepared above.
  • the cells in the present invention may be either eukaryotic cells or prokaryotic cells, for example, cells derived from mammals, birds, reptiles, amphibians, fishes, insects or plants, microorganisms such as bacteria, Escherichia coli or Bacillus subtilis, bacteria. , Cells derived from microorganisms such as Escherichia coli or Bacillus subtilis, or cells derived from yeast or the like. It is preferably animal cells belonging to mammals, more preferably animal cells derived from primates such as human or monkey or animal cells derived from rodents such as mouse, rat or hamster, most preferably Chinese hamster ovary tissue. CHO cells may be mentioned.
  • the cells belonging to the mammal in the present invention preferably include myeloma cells, ovary cells, kidney cells, blood cells, uterine connective tissue cells, mammary gland cells, embryonic retinoblasts or cells derived from these cells.
  • myeloma cells, cells derived from myeloma cells, ovary cells or cells derived from ovarian cells is more preferred.
  • human cell lines HL-60 (ATCC No. CCL-240), HT-1080 (ATCC No. CCL-121), HeLa (ATCC No. CCL-2), 293 (ECACC No. 85120602), Namalwa. (ATCC CRL-1432), Namalwa KJM-1 [Cytotechnology, 1, 151 (1978)], NM-F9 (DSM ACC2605, International Publication No. 2005/017130) or PER. C6 (ECACC No. 96022940, US Pat. No. 6,855,544), monkey cell lines VERO (ATCC No. CCL-1651) and COS-7 (ATCC No. CRL-1651), mouse cell line C127I ( ATCC No.
  • CRL-1616 Sp2 / 0-Ag14 (ATCC No. CRL-1581) or NIH3T3 (ATCC No. CRL-1658) NS0 (ATCC No. CRL-1827), a rat cell line Y3 Ag1.2. 3.3. (ATCC No. CRL-1631), YO (ECACC No. 85110501) or YB2 / 0 (ATCC No. CRL-1662), ham cell line CHO cells or BHK21 (ATCC No. CRL-10), or dog cell. MDCK (ATCC No. CCL-34) and the like.
  • Examples of cells belonging to birds include chicken cell line SL-29 (ATCC No. CRL-29) and the like.
  • Examples of cells belonging to fish include zebrafish cell line ZF4 (ATCC No. CRL-2050).
  • Examples of cells belonging to insects include a moth (Spodoptera frugiperda) cell line Sf9 (ATCC No. CRL-1711).
  • Examples of the primary culture cells used for vaccine production include primary monkey kidney cells, primary rabbit kidney cells, primary chicken fetal cells, primary quail fetal cells, and the like.
  • the CHO cells in the present invention include any cell established as long as it is a cell line established from the ovarian tissue of Chinese hamster (Cricetulus griseus). Specific examples include Journal of Experimental Medicine, 108, 945 (1958), Proc. Natl. Acad.Sci. USA, 60, 1275 (1968), Genetics, 55, 513 (1968), Chromosoma, 41, 129 (1973), Methods in Cell Science, 18, 18, 115 (1996), Radiation Research, 148, 260 (1997), Proc. Natl. Acad. Sci. USA, 77, 4216 (1980), Proc. Natl.Acad. Examples include CHO cells described in documents such as Sci.
  • CHO-K1 strain ATCC No. CCL-61
  • DUXB11 strain ATCC CRL-9096
  • Pro-5 strain ATCC CRL-1781
  • CHO / which are registered in ATCC (The American Type Culture Collection).
  • dhfr- ATCC No. CRL-9096
  • commercially available CHO-S strain (Lifetechnologies Cat # 11619), CHO / DG44 [Proc. Natl. Acad. Sci. USA, 77, 4216 (1980)] or these strains.
  • Specific examples include sub-strains acclimated to various media.
  • the cell in the present invention is not particularly limited to the ability to produce a substance, and examples thereof include stem cells such as iPS cells obtained by introducing several kinds of genes into somatic cells, and mammalian donors including humans. Examples thereof include sperm or egg cells collected from the above, cells producing a substance, and fused cells producing a substance. Particularly preferably, a cell producing a substance, or a fused cell adapted to produce a substance can be mentioned. More preferably, an animal cell that produces a substance or a fused cell derived from an animal that has come to produce a substance can be used. For example, when the desired substance is an antibody, an antibody-producing cell such as a B cell is used.
  • stem cells such as iPS cells obtained by introducing several kinds of genes into somatic cells, and mammalian donors including humans. Examples thereof include sperm or egg cells collected from the above, cells producing a substance, and fused cells producing a substance.
  • Examples include hybridomas that are fused cells with myeloma cells.
  • the cells of the present invention also include cells that have become able to produce a substance by mutation treatment, cells that have been subjected to a mutation treatment that increases the expression level of the substance, and the like.
  • Examples of cells that have become able to produce a substance by the mutation treatment in the present invention include cells in which a mutation has been introduced into a modifying enzyme or the like so that a desired substance can be produced.
  • a modifying enzyme or the like so that a desired substance can be produced.
  • the desired substance is a glycoprotein
  • the cell producing the substance in the present invention may be any cell as long as it can produce the desired substance, for example, it was transformed with a recombinant vector containing a gene involved in the production of the substance. Cells are also included.
  • the transformed cell can be obtained by, for example, introducing a recombinant vector containing a DNA involved in the production of the substance and a promoter into a host cell.
  • Examples of the gene involved in the production of the substance in the present invention include DNA encoding a substance such as peptide, polypeptide, protein, glycoprotein or antibody, DNA encoding an enzyme or protein involved in the biosynthesis of the substance, and the like. Be done.
  • any promoter can be used, so long as it functions in cells.
  • the promoter of the immediate early (IE) gene of cytomegalovirus (CMV) the early promoter of SV40, the promoter of retrovirus.
  • a metallothionein promoter a heat shock promoter, an SR ⁇ promoter and the like.
  • an enhancer of the IE gene of human CMV and the like may be used together with the promoter.
  • the recombinant vector of the present invention can be prepared using a desired vector.
  • any vector can be used as long as it functions in cells.
  • pcDNAI, pcDM8 manufactured by Funakoshi Co., Ltd.
  • pAGE107 [JP-A-3-22979, Cytotechnology, 3, 133, (1990) )]
  • PAS3-3 JP-A-2-227075
  • pcDM8 [Nature, 329, 840, 1987]]
  • pcDNAI / Amp manufactured by Invitrogen
  • pREP4 manufactured by Invitrogen
  • pAGE103 J. Biochem., 101, 1307 (1987)] or pAGE210.
  • any method can be used as long as it is a method for introducing DNA into a cell.
  • electroporation [Cytotechnology, 3, 133, (1990) )]
  • Calcium phosphate method JP-A-2-227075
  • lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987), Virology, 52, 456 (1973)], etc. ..
  • transformant cell in the present invention examples include transformant cell 7-9-51 (FERM BP-6691) that produces an anti-GD3 human chimeric antibody, and transformant cell KM2760 (FERM BP- that produces an anti-CCR4 chimeric antibody). 7054), anti-CCR4 humanized antibody-producing transformed cells KM8759 (FERM BP-8129) and KM8760 (FERM BP-8130), 709 LCA-500D (FERM BP-8239), anti-IL-5 receptor ⁇ chain chimera.
  • transformant cell 7-9-51 (FERM BP-6691) that produces an anti-GD3 human chimeric antibody
  • transformant cell KM2760 transformant cell KM2760
  • 7054 anti-CCR4 humanized antibody-producing transformed cells KM8759 (FERM BP-8129) and KM8760 (FERM BP-8130), 709 LCA-500D (FERM BP-8239), anti-IL-5 receptor ⁇ chain chimera.
  • Antibody-producing transformant KM7399 (FERM BP-5649), anti-IL-5 receptor ⁇ chain human CDR-grafted antibody-producing transformant KM8399 (FERM BP-5648) and KM9399 (FERM BP-5647), Anti-GM2 human CDR-grafted anti Transformed cells producing body KM8966 (FERM BP-5105), KM8967 (FERM BP-5106), KM8969 (FERM BP-5527), KM8970 (FERM BP-5528), anti-CD20 antibody producing transformant Ms704- Transformed cells that produce CD20 (FERM BP-10092) and antithrombin III, Ms705-pKAN-ATIII (FERM BP-8472) and the like.
  • Examples of the method for culturing cells in the present invention include methods suitable for the cells to be used, such as batch culture, repeat batch culture, rolling seed culture, fed batch culture or perfusion culture, and preferably fed batch culture is used.
  • the culture is carried out under conditions of pH 6 to 8 and 30 to 40 ° C. for 3 to 20 days in fed-batch culture and 3 to 60 days in perfusion culture.
  • an antibiotic such as streptomycin or penicillin may be added to the medium during the culturing.
  • the dissolved oxygen concentration control, pH control, temperature control, stirring and the like can be carried out by a method used for usual cell culture.
  • the culturing amount in the culturing method of the present invention is a very small culturing amount of usually 0.1 mL to 10 mL using a cell culturing plate, a small culturing amount of usually 10 to 1000 mL using an Erlenmeyer flask, a jar, etc.
  • the culture amount may be a large amount that can be used for commercial production of 1 to 20000 L in a culture tank or the like, or any culture amount.
  • the present invention also comprises culturing cells expressing a desired polypeptide in the liquid medium prepared as described above, producing and accumulating the polypeptide in the culture, and collecting the polypeptide from the culture.
  • the present invention relates to a method for producing a polypeptide, or a polypeptide produced by using the method.
  • any polypeptide may be used as long as it is a peptide in which amino acids are peptide-bonded, but preferably a eukaryotic cell-derived polypeptide, more preferably an animal cell-derived polypeptide, for example, , And polypeptides derived from mammalian cells.
  • the polypeptide of the present invention may be, for example, an artificially modified polypeptide such as a fusion peptide obtained by fusing a desired polypeptide with another polypeptide, or a polypeptide consisting of a partial fragment. It may be a peptide.
  • a polypeptide having physiological activity can be mentioned.
  • polypeptide in the present invention examples include a protein, a glycoprotein, an antibody, a polypeptide comprising a partial fragment thereof, and the like.
  • the polypeptide of the present invention also includes, for example, a polypeptide that regulates the activity of an enzyme or a polypeptide that retains the structure of the enzyme.
  • Specific examples of the polypeptide that regulates the activity of the enzyme include a polypeptide that functions as a glycoprotein agonist or antagonist.
  • the agonist may be any polypeptide as long as it has an activity of enhancing the activity of glycoprotein, and specifically, somatostatin derivative, somatrobin, atrial natriuretic peptide, glucagon, insulin, insulin-like growth factor or gonad Examples include stimulating hormone.
  • the antagonist may be any polypeptide as long as it has an activity of suppressing the activity of glycoprotein, and specific examples thereof include pegvisomaton.
  • EPO erythropoietin
  • TPO thrombopoietin
  • TPO Tissue-type plasminogen activator
  • prourokinase thrombomodulin
  • antithrombin III protein C
  • protein S blood coagulation factor VII
  • blood coagulation factor VIII blood coagulation factor IX
  • blood coagulation factor X blood coagulation factor XI
  • blood coagulation factor XII prothrombin complex
  • fibrinogen albumin, gonadotropin
  • thyroid stimulating hormone epidermal growth factor (EGF), hepatocyte growth factor (HGF), keratinocyte growth factor, activin, bone morphogenetic factor, stem cell factor (SCF), granules Sphere colony-stimulating factor (G-CSF) [J.Biol.Chem., 258, 9]
  • GM-CSF Granulocyte-macrophage colony stimulating factor
  • IL-2 interleukin-2
  • IL-12 Interleukin-12
  • soluble interleukin 4 receptor tumor necrosis factor ⁇
  • DNase I galactosidase
  • glucosidase glucocerebrosidase
  • hemoglobin hemoglobin.
  • Transferrin derivatives thereof, partial fragments thereof, and the like.
  • the antibody in the present invention may be any antibody as long as it has an antigen-binding activity, for example, an antibody recognizing a tumor-associated antigen or an antibody fragment thereof, an antibody recognizing an antigen associated with allergy or inflammation, or an antibody fragment thereof.
  • Tumor-associated antigens in the present invention include CD1a, CD2, CD3, CD4, CD5, CD6, CD7, CD9, CD10, CD13, CD19, CD20, CD21, CD22, CD25, CD28, CD30, CD32, CD33, CD38, CD40.
  • CD40 ligand (CD40L) CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD56, CD59, CD63, CD64, CD66b, CD69, CD70, CD74, CD80, CD89, CD95, CD98, CD105, CD134, CD137.
  • ARP4 angiopoietin related protein 4
  • aurora aurora
  • B7-H1, B7-DC integrin
  • BST2 bone marrow stromal antigen 2
  • CA9 carbonic anhydrase 9
  • cadherin c ceremone
  • E-catherin epidermal growth factor receptor (EGFR), EGFRvIII, EGFR2 (HER2), EGFR3 (HER3), EGFR4 (HER4), endoglutinal, epithelial, epithelial cell, EGFR2 (HER3) , Ephrin receptor (Eph), EphA2, endothelase-2 (ET2), FAM3D, fibroblast activating protein (FAP), Fc receptor homologue 1 (FcRH1), ferribrogine, fibrot.
  • FGF8 wthfactor8
  • FGF8 receptor basic FGF
  • bFGF basic FGF
  • bFGF receptor FGF receptor
  • FGF receptor FGFR 3
  • FLT1, FLTzfredo4 FLTzfredo4 (fretoceptor, frizzledo), brate receptor, frizlezfredo (freqrezfr)
  • HM1.24 uman milk fat globule (HMFG), hRS7, heat shock protein 90 (hsp90), idiotype epitopepe, insulin-like aggregate-IL15-IL- or 15-factor (IGF), IGF receptor-IL (IGF) receptor-IGR (IGF).
  • HMFG milk fat globule
  • hRS7 heat shock protein 90
  • idiotype epitopepe insulin-like aggregate-IL15-IL- or 15-factor (IGF), IGF receptor-IL (IGF) receptor-IGR (IGF).
  • IL-6R or IL-15R etc. integrin, immune receptor translocation associated-4 (IRTA-4), kallikrein 1, KDR, KIR2DL1, KIR2DL2 / 3, KS1 / 4, ramp-1, lamp-2, laminin- 5, Lewis y, si lyl Lewis x, lymphotoxin-beta receptor (LTBR), LUNX, melanoma-associated chondroitin sulfate proteoglycan (MCSP), mesothelin, MICA, Mullerian inhibiting substance type II receptor (MISIIR), mucin, neural cell adhesion molecule (NCAM), Necl- 5, Notch1, osteopontin, platelet-delivered growth factor (PDGF), PDGF receptor, platelet factor-4 (PF-4), phosphotide ylserine, Prostate Specific Antigen (PSA), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), Parathyroid hormone related protein / peptide (PTHrP), receptor activ
  • TIM-1 immunoglobulin domain and mucin domain 1
  • human tissue factor hTF
  • Tn antigen tumor necrosisNefrentenfactor
  • FN tumor necrosisNefrentenfactor
  • FN tumor necrosisNefrentenfactor
  • FN tumor necrosisNefrentenfactor
  • TRAIL TRAIL receptor
  • DR4 or DR5, etc. system ASC amino acid transporter 2
  • ASCT2 system ASC amino acid transporter 2
  • trkC TROP-2
  • TWEAK receptor Fn14 type IV collagenase, urokinase receptor, vascular endothelial growth Factor (VEGF), VEGF receptor (VEGFR1, VEGFR2 or VEGFR3 etc.), vimentin or VLA-4 etc.
  • the antibody in the present invention may be either a monoclonal antibody or a polyclonal antibody, and the antibody classes include immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin M (IgM). ) Are mentioned, but IgG is preferable. Further subclasses of IgG include IgG1, IgG2, IgG3 or IgG4.
  • the antibody of the present invention includes a partial fragment containing a part of the antibody, and includes, for example, Fab (Fragment of antigen binding), Fab ′, F (ab ′) 2, single chain antibody (single chain Fv, scFv). And a disulfide stabilized antibody (disulfide stabilized Fv, dsFv), or a fusion protein containing the Fc region of the antibody.
  • the antibody in the present invention includes, for example, an antibody secreted by hybridoma cells prepared from spleen cells of an immunized animal by immunizing an animal with the antigen, or an antibody prepared by a gene recombination technique.
  • the antibody produced by the gene recombination technique can be obtained by, for example, introducing an antibody expression vector into which an antibody gene is inserted into a host cell.
  • Specific examples include an antibody produced by a hybridoma, a human chimeric antibody, a humanized antibody and a human antibody.
  • the human chimeric antibody of the present invention includes an antibody heavy chain variable region of a non-human animal (hereinafter, a heavy chain is an H chain, a variable region is a V region, and is also referred to as HV or VH, respectively) and an antibody light chain variable region (
  • the light chain is referred to as an L chain and is also referred to as LV or VL, respectively
  • a human antibody heavy chain constant region hereinafter, the constant region is also referred to as a C region and is also referred to as CH
  • CL human antibody light chain constant region
  • any animal such as mouse, rat, hamster or rabbit can be used as long as a hybridoma can be produced.
  • the human chimeric antibody is obtained by obtaining cDNAs encoding VH and VL from a hybridoma derived from a non-human animal cell producing a monoclonal antibody, and using it as an expression vector for host cells having genes encoding human antibody CH and human antibody CL. It can be obtained by inserting each to construct a human chimeric antibody expression vector and introducing the expression vector into a host cell to express the expression.
  • the CH of the human chimeric antibody may be any as long as it belongs to human immunoglobulin (hereinafter referred to as hIg), but hIgG class is preferable, and further hIgG1, hIgG2, hIgG3 or hIgG4 belonging to hIgG class is preferable. Any of the subclasses such as can be used.
  • the CL of the human chimeric antibody may be any CL as long as it belongs to hIg, and those of ⁇ class or ⁇ class can be used.
  • humanized antibody in the present invention for example, an amino acid sequence of a human type homology determining region (Complementarity Determining Region, hereinafter referred to as CDR) of VH and VL of a non-human animal antibody Examples thereof include CDR-grafted antibody produced by transplanting into an appropriate position.
  • CDR Human type homology determining region
  • the CDR-grafted antibody is a human antibody CH and human antibody constructed by constructing a cDNA encoding a V region by grafting VH and VL CDR sequences of a non-human animal antibody onto VH and VL CDR sequences of any human antibody. It can be obtained by inserting each of them into a host cell expression vector having a gene encoding CL to construct a CDR-grafted antibody expression vector, and introducing the expression vector into a host cell for expression.
  • any CH may be used as long as it belongs to hIg, but hIgG class is preferable, and any subclass such as hIgG1, hIgG2, hIgG3, or hIgG4 belonging to the hIgG class can be used.
  • any CL may be used as long as it belongs to hIg, and a ⁇ class or a ⁇ class can be used.
  • the human antibody of the present invention can be obtained by, for example, culturing and purifying human antibody-producing lymphocytes obtained by isolating human peripheral blood lymphocytes, infecting them with EB virus, immortalizing and cloning. it can.
  • the human antibody of the present invention can be obtained by inserting an antibody gene prepared from human B cells into a phage gene to obtain a human antibody phage library in which antibody fragments such as Fab and scFv are expressed on the phage surface.
  • a human antibody phage library in which antibody fragments such as Fab and scFv are expressed on the phage surface.
  • a human antibody-producing hybridoma obtained by a method for producing a hybridoma or the like, which is usually carried out in a mammal other than human, from a human antibody-producing transgenic animal animal in which a human antibody gene is incorporated into a cell. ..
  • a human antibody-producing transgenic mouse by introducing a human antibody gene into a mouse ES cell, transplanting the ES cell into an early embryo of a mouse, and then developing it to obtain a human antibody-producing hybridoma. it can.
  • the human antibody can be obtained by inserting each into an expression vector for a host cell having DNA encoding CL and CH and expressing by introducing into a host cell.
  • cDNAs encoding VL and VH are obtained from a human antibody-producing hybridoma and inserted into expression vectors for host cells having DNAs encoding CL and CH of human antibody, respectively, and the WT It is also possible to obtain a human antibody by constructing a human antibody expression vector by substituting Cys residue for one or more amino acid residues and introducing it into an animal cell for expression.
  • the WT CH used for the human antibody may be any CH as long as it belongs to hIg, preferably hIgG class is used, and any subclass such as hIgG1, hIgG2, hIgG3 or hIgG4 belonging to hIgG class is used.
  • the CL of the human antibody may be any CL as long as it belongs to hIg, and a ⁇ class or a ⁇ class can be used.
  • Examples of the antibody in the present invention include, but are not limited to, the following antibodies.
  • antibodies that recognize tumor-associated antigens include anti-GD2 antibody [Anticancer Res., 13, 331 (1993)], anti-GD3 antibody [Cancer Immunol. Immunother., 36, 260 (1993)], anti-GM2 antibody [ Cancer Res., 54, 1511 (1994)], anti-HER2 antibody [Proc.Natl. Acad. Sci. USA, 89, 4285 (1992), US Pat. No. 5,725,856], anti-CD52 antibody [Proc.Natl. Acad. Sci.
  • anti-CEA antibody [Cancer Res] ., 55 (23 suppl): 5935s-5945s, (1995)], anti-CD38 antibody, anti-CD33 antibody, anti-CD22 antibody, anti-EpCAM antibody, anti-A33 antibody, and the like.
  • Antibodies that recognize antigens related to allergy or inflammation include, for example, anti-interleukin 6 antibody [Immunol. Rev., 127, 5 (1992)], anti-interleukin 6 receptor antibody [Molecular Immunol., 31, 371 (1994)], anti-interleukin 5 antibody [Immunol. Rev., 127, 5 (1992)], anti-interleukin 5 receptor antibody, anti-interleukin 4 antibody [Cytokine, 3, 562 (1991)], anti-interleukin 5 antibody Leukin 4 receptor antibody [J. Immunol.
  • Antibodies that recognize antigens related to cardiovascular disease include, for example, anti-GPIIb / IIIa antibody [J. Immunol., 152, 2968 (1994)], anti-platelet-derived growth factor antibody [Science, 253, 1129 (1991). ], Antiplatelet-derived growth factor receptor antibody [J. Biol.Chem., 272, 17400 (1997)], anticoagulation factor antibody [Circulation, 101, 1158 (2000)], anti-IgE antibody, anti- ⁇ V ⁇ 3 antibody or Examples include ⁇ 4 ⁇ 7 antibody.
  • Antibodies that recognize antigens associated with viral or bacterial infections include anti-gp120 antibody [Structure, 8,385 (2000)], anti-CD4 antibody [J. Rheumatology, 25,2065 (1998)], anti-CCR5 antibody or anti-CCR5 antibody. Verotoxin antibody [J. Clin. Microbiol., 37, 396 (1999)] and the like.
  • the method for producing the polypeptide of the present invention for example, a direct expression method for producing the polypeptide in the cell or a method for secreting and producing the polypeptide outside the cell (Molecular Cloning 2nd edition) can be used.
  • the polypeptide of the present invention is obtained by the method of Paulson et al. [J. Biol. Chem., 264, 17619 (1989)], the method of Law [Proc. Natl. Acad. Sci. USA, 86, 8227 (1989), Genes Develop., 4, 1288 (1990)], Japanese Patent Laid-Open No. 5-336963, or International Publication No. 1994/23021. it can. That is, a desired polypeptide can be positively secreted outside the host cell by using a gene recombination technique to express the desired polypeptide in a form in which a signal peptide is bound to the N-terminus.
  • the production amount of the polypeptide can be increased by utilizing a gene amplification system described in Japanese Patent Laid-Open No. 2-227075, which uses a dihydrofolate reductase gene or the like.
  • polypeptide produced by the method of the present invention can be isolated and purified using, for example, a general polypeptide isolation and purification method.
  • the cells are collected by centrifugation, suspended in an aqueous buffer solution, ultrasonically disrupted, French press, Mantongaulin homogenizer or Dynomill.
  • the cells are disrupted by, for example, to obtain a cell-free extract.
  • a usual peptide or protein isolation and purification method that is, a solvent extraction method, a salting-out method using ammonium sulfate, a desalting method, a precipitation method using an organic solvent, etc.
  • the polypeptide can be recovered in the culture supernatant. That is, the culture supernatant is obtained by treating the culture by a method such as centrifugation similar to the above, and from the culture supernatant, a crude purified sample is prepared by using the same isolation and purification method as described above. Alternatively, a purified standard can be obtained.
  • the present invention also relates to a method for controlling the production of a variant derived from a polypeptide using the prepared liquid medium in the step of culturing cells expressing the polypeptide.
  • the polypeptide-derived variant in the present invention is not particularly limited, but includes, for example, a desired polypeptide-derived modified product, a glycated product, an oxidized product, a sugar chain modified product such as a high mannose product, a polymer or a degradation product. Can be mentioned.
  • the content can be adjusted at an arbitrary content rate, for example, a variant derived from a desired polypeptide that changes depending on the concentration of copper in the liquid medium Generation can be controlled.
  • the amount of the variant derived from the polypeptide in the present invention can be measured using, for example, a separation method by ion exchange chromatography.
  • a separation method by ion exchange chromatography For example, when an antibody is analyzed by cation exchange column chromatography, the peak that elutes earlier than the main peak usually contains an acidic variant with a low pI value, and is called an acidic peak (hereinafter also referred to as acidic peaks).
  • the component eluted after the main peak contains a basic variant with a high pI value, and is called a basic peak (hereinafter also referred to as basic peaks).
  • Example 1 Effect of oxygen on / off of copper during preparation of medium The effect of oxygen concentration in the medium upon preparation of liquid medium containing powder medium on the copper concentration in the medium after preparative filtration was evaluated. ..
  • the medium was prepared by the following procedure. First, pure water was added to each of the two preparation vessels. On one side, air was ventilated from the lower surface to saturate the dissolved oxygen concentration. On the other side, nitrogen was ventilated from the lower surface to remove dissolved oxygen out of the system. Powder medium A (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) containing the amino acids, metal salts, vitamins, etc.
  • Example 2 Evaluation of oxygen supply amount for dissolving copper in culture medium Evaluation of influence of dissolved oxygen concentration in culture medium during preparation of liquid medium containing powder medium on copper concentration in medium after preparative filtration did.
  • the medium was prepared by the following procedure.
  • Example 3 Relationship between copper concentration in medium and quality of produced antibody The quality of the prepared antibody was confirmed using a medium in which the copper concentration in the medium after filtration was changed by the dissolved oxygen concentration during medium preparation. , It was clarified that the content of variant can be adjusted in a concentration-dependent manner.
  • An antibody was prepared by culturing CHO cells that produce IgG type monoclonal antibody using the four types of liquid medium prepared in Example 3. The medium preparation and analysis were performed by the following procedure.
  • CHO cells incorporating the antibody gene were seeded on each medium prepared in Example 3, and fed batch culture was performed while adding additives such as amino acids and glucose to produce the desired antibody. After the culture was completed, the cells were removed and the culture supernatant was collected to purify the antibody. Variants were detected in the purified antibody by high performance liquid chromatography using a cation exchange chromatography column. Among the variants detected by cation exchange chromatography, the peaks (basic peaks) containing the basic variant were compared with the copper concentration in the medium.
  • the concentration of dissolved oxygen in the medium is changed, the concentration of copper in the medium after filtration is changed, and the ratio of the basic peaks of the antibody produced by the animal cells is reduced in a copper concentration-dependent manner. It was clarified that the ratio of basic peaks can be adjusted according to
  • the present invention provides a preparation method in which the concentration of copper in a liquid medium is not substantially changed before and after membrane filtration when a powder medium containing copper and cysteine, cystine or a derivative thereof is dissolved in a solvent.
  • Liquid medium prepared by the preparation method, method for culturing cells using the liquid medium prepared by the preparation method, method for producing a physiologically active substance using the culture method, and physiological activity produced by the production method Substance, method of membrane filtration of liquid medium prepared by the preparation method, method in which copper is not removed by membrane filtration by adjusting the supply amount of dissolved oxygen, or liquid medium is prepared, membrane filtration, and the liquid
  • a method for producing a physiologically active substance by culturing cells using a medium is provided.

Abstract

L'invention concerne un procédé de préparation de milieu de culture liquide caractéristique en ce qu'un composant prédéfini est dissous de manière efficace par régulation de la quantité d'alimentation en oxygène, un milieu de culture liquide préparé selon ce procédé de préparation, un procédé de culture de cellules mettant en œuvre le milieu de culture liquide ainsi préparé selon le procédé de préparation, un procédé de fabrication de substance active physiologiquement ayant la qualité souhaitée qui met en œuvre ce procédé de culture, et une substance active physiologiquement ayant la qualité souhaitée qui est fabriquée par mise en œuvre de ce procédé de fabrication.
PCT/JP2019/043031 2018-11-02 2019-11-01 Procédé de préparation de milieu de culture liquide WO2020091041A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/290,365 US20210403971A1 (en) 2018-11-02 2019-11-01 Method for preparing liquid medium
EP19878782.2A EP3875595A4 (fr) 2018-11-02 2019-11-01 Procédé de préparation de milieu de culture liquide
JP2020554981A JP7453151B2 (ja) 2018-11-02 2019-11-01 液体培地の調製方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754793P 2018-11-02 2018-11-02
US62/754,793 2018-11-02

Publications (1)

Publication Number Publication Date
WO2020091041A1 true WO2020091041A1 (fr) 2020-05-07

Family

ID=70463393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/043031 WO2020091041A1 (fr) 2018-11-02 2019-11-01 Procédé de préparation de milieu de culture liquide

Country Status (4)

Country Link
US (1) US20210403971A1 (fr)
EP (1) EP3875595A4 (fr)
JP (1) JP7453151B2 (fr)
WO (1) WO2020091041A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190689A1 (fr) * 2022-03-30 2023-10-05 富士フイルム株式会社 Procédé de production de poudre mélangée, poudre mélangée, poudre et milieu de culture en poudre

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023194946A1 (fr) * 2022-04-06 2023-10-12 Kashiv Biosciences, Llc Procédé de culture cellulaire amélioré pour la production de protéine

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1996030046A1 (fr) 1995-03-30 1996-10-03 Genentech, Inc. Antagonistes de facteurs de croissance des cellules endotheliales vasculaires
WO1996040201A1 (fr) 1995-06-07 1996-12-19 Chiron Corporation Banques combinatoires de composes organiques cycliques lies a un substrat
US5725856A (en) 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1998051793A1 (fr) 1997-05-15 1998-11-19 Genentech, Inc. RECEPTEUR D'Apo-2
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2005017130A2 (fr) 2003-08-18 2005-02-24 Glycotope Gmbh Lignees cellulaires tumorales et utilisations associees
WO2010008075A1 (fr) 2008-07-17 2010-01-21 協和発酵キリン株式会社 Anticorps anti-transporteur aminoacide système asc 2 (asct2)
WO2012091023A1 (fr) * 2010-12-27 2012-07-05 協和発酵キリン株式会社 Procédé d'élaboration d'une solution aqueuse contenant un milieu de culture et un agent chélatant
JP2018068279A (ja) * 2012-04-16 2018-05-10 レツク・フアーマシユーテイカルズ・デー・デー タンパク質発現のための細胞株におけるアミド化アミノ酸形成の減少

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
WO2014145098A1 (fr) * 2013-03-15 2014-09-18 Genentech, Inc. Compositions de culture cellulaire ayant anti-oxydants et procédés pour une production de polypeptide
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
KR102499718B1 (ko) * 2016-06-10 2023-02-13 론자 리미티드 단백질을 안정화시키는 방법

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725856A (en) 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1996030046A1 (fr) 1995-03-30 1996-10-03 Genentech, Inc. Antagonistes de facteurs de croissance des cellules endotheliales vasculaires
WO1996040201A1 (fr) 1995-06-07 1996-12-19 Chiron Corporation Banques combinatoires de composes organiques cycliques lies a un substrat
WO1998051793A1 (fr) 1997-05-15 1998-11-19 Genentech, Inc. RECEPTEUR D'Apo-2
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2005017130A2 (fr) 2003-08-18 2005-02-24 Glycotope Gmbh Lignees cellulaires tumorales et utilisations associees
WO2010008075A1 (fr) 2008-07-17 2010-01-21 協和発酵キリン株式会社 Anticorps anti-transporteur aminoacide système asc 2 (asct2)
WO2012091023A1 (fr) * 2010-12-27 2012-07-05 協和発酵キリン株式会社 Procédé d'élaboration d'une solution aqueuse contenant un milieu de culture et un agent chélatant
JP2018068279A (ja) * 2012-04-16 2018-05-10 レツク・フアーマシユーテイカルズ・デー・デー タンパク質発現のための細胞株におけるアミド化アミノ酸形成の減少

Non-Patent Citations (65)

* Cited by examiner, † Cited by third party
Title
BRITISH J. CANCER, vol. 83, 2000, pages 493
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 260
CANCER RES., vol. 54, 1994, pages 1511
CANCER RES., vol. 55, no. 23, pages 5935s - 5945s
CANCER RES., vol. 57, 1997, pages 4593
CANCER, vol. 88, 2000, pages 2909
CELL, vol. 6, 1975, pages 121
CHROMOSOMA, vol. 41, 1973, pages 129
CIRCULATION, vol. 101, 2000, pages 1158
CURR. OPIN. ONCOL., vol. 10, 1998, pages 548
CYTOKINE, vol. 3, 1991, pages 562
CYTOTECHNOLOGY, vol. 3, 1990, pages 133 - 900
D. BRUHLMANN ET AL., BIOTECHNOLOGY PROGRESS, vol. 31, 2015, pages 615 - 629
GENES DEVELOP., vol. 4, 1990, pages 1288
GENETICS, vol. 55, 1968, pages 513
HYBRIDOMA, vol. 13, 1994, pages 183
IMMUNOL. REV., vol. 127, 1992, pages 5
J. BIOCHEM., vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 252, 1977, pages 1998
J. BIOL. CHEM., vol. 258, 1983, pages 9017
J. BIOL. CHEM., vol. 265, 1990, pages 16455
J. BIOL. CHEM., vol. 272, 1997, pages 17400
J. CLIN. MICROBIOL., vol. 37, 1999, pages 396
J. EXP. MED., vol. 173, 1992, pages 269
J. EXP. MED., vol. 186, 1997, pages 1373
J. EXPERIMENTAL MEDICINE, vol. 147, 1978, pages 923
J. IMMUNOL. METHODS, vol. 217, 1998, pages 41
J. IMMUNOL., vol. 152, 1994, pages 2968
J. LEUC. BIOL., vol. 55, 1994, pages 280
J. NEUROSCI. RES., vol. 40, 1995, pages 647
J. RHEUMATOLOGY, vol. 25, 1998, pages 2065
J. UROLOGY, vol. 160, 1998, pages 2396
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 108, 1958, pages 945
K.A. JOHNSON ET AL., ANAL BOCHEM, 2007
LOWE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 8227
MAYER, R. A. ET AL.: "Preparation of media and buffers with soluble lead", ANALYTICAL BIOCHEMISTRY, vol. 356, 2006, pages 142 - 144, XP024942068, DOI: 10.1016/j.ab.2006.02.032 *
METHODS IN CELL SCIENCE, vol. 18, 1996, pages 115
MOLECULAR IMMUNOL., vol. 31, 1994, pages 371
MOLECULAR IMMUNOL., vol. 36, 1999, pages 387
MOLECULAR PHARMACOL., vol. 58, 2000, pages 237
NATURE, vol. 329, 1987, pages 840
NATURE, vol. 369, 1994, pages 533
NATURE, vol. 400, 1999, pages 776
ONCOGENE, vol. 19, 2000, pages 2138
PAULSON ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 17619
PERI ET AL., J. IMMUNOL. METH., vol. 174, 1994, pages 249
PROC. NATL. ACAD. SCI. USA, vol. 53, 1965, pages 288
PROC. NATL. ACAD. SCI. USA, vol. 60, 1968, pages 1275
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285
PROC. NATL. ACAD. SCI., vol. 60, 1968, pages 1275
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
R. J. HAY ET AL., NATURE, vol. 339, 1989, pages 487 - 488
RADIATION RESEARCH, vol. 148, 1997, pages 260
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 193, 1976, pages 1007
SCIENCE, vol. 253, 1991, pages 1129
See also references of EP3875595A4
STRUCTURE, vol. 8, 2000, pages 385
T. KASCHAK ET AL., MABS, vol. 6, 2011, pages 577 - 583
TAILORING RECOMBINANT PROTEIN QUALITY BY RATIONAL MEDIA DESIGNBIOTECHNOL. PROG., vol. 31, no. 3, 2015, pages 615 - 629
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
VIROLOGY, vol. 52, 1973, pages 456
VIROLOGY, vol. 8, 1959, pages 396

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190689A1 (fr) * 2022-03-30 2023-10-05 富士フイルム株式会社 Procédé de production de poudre mélangée, poudre mélangée, poudre et milieu de culture en poudre

Also Published As

Publication number Publication date
US20210403971A1 (en) 2021-12-30
JPWO2020091041A1 (ja) 2021-09-30
EP3875595A1 (fr) 2021-09-08
JP7453151B2 (ja) 2024-03-19
EP3875595A4 (fr) 2022-07-13

Similar Documents

Publication Publication Date Title
JP6943972B2 (ja) 灌流培地
US20130130317A1 (en) Method for producing substance
JP6797950B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現
EP2653540B9 (fr) Procédé de production d'une protéine
JP7453151B2 (ja) 液体培地の調製方法
US20200299723A1 (en) Animal cell, method for producing animal cell, and method for producing target protein
JP2007500016A (ja) 培養においてタンパク質生成を増大させるための方法
US9611458B2 (en) Method for preparing aqueous solution containing culture medium and chelating agent
EP3158055B1 (fr) Production améliorée du facteur de von willebrand recombinant dans un bioréacteur
WO2022225060A1 (fr) Procédé de suppression de la production de produits de dégradation
US9976163B2 (en) Method for preventing reduction of polypeptide by adding amino acid to culture solution
JP7123168B2 (ja) 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法
WO2020122048A1 (fr) Cellules animales, procédé de production de cellules animales et procédé de production de protéine cible
WO2023079058A1 (fr) Culture cellulaire avec production réduite de lactate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19878782

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020554981

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019878782

Country of ref document: EP

Effective date: 20210602